Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.61 |
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | TSHR | P16473 | 2/20 | 0.61 |
| ▸ | BLM | P54132 | 2/20 | 0.61 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | MPO | P05164 | 1/20 | 0.61 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.61 |
| ▸ | HTR2A | P28223 | 4/20 | 0.58 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.56 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.56 |
| ▸ | HTR6 | P50406 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | HTR1A | P08908 | 1/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18029216 | 1.00 | KMT2A (0.61) | KMT2AKDM4EMAPTLMNATSHR | |
| SCHEMBL1461062 | 1.00 | KMT2A (0.61) | KMT2AKDM4EMAPTLMNATSHR | |
| SCHEMBL29809866 | 1.00 | KMT2A (0.61) | KMT2AKDM4EMAPTLMNATSHR | |
| SCHEMBL2013303 | 1.00 | KMT2A (0.61) | KMT2AKDM4EMAPTLMNATSHR | |
| SCHEMBL2013301 | 0.89 | MTNR1A (0.58) | KMT2AKDM4EMAPTLMNATSHR | |
| Hydrochloric Acid SCHEMBL28174730 | 0.88 | MTNR1A (0.57) | KMT2AKDM4EMAPTLMNATSHR | |
| Hydrochloric Acid SCHEMBL28174732 | 0.88 | MTNR1A (0.57) | KMT2AKDM4EMAPTLMNATSHR | |
| SCHEMBL24328917 | 0.86 | SMN1; SMN2 (0.60) | KMT2AKDM4EMAPTLMNATSHR | |
| SCHEMBL28409765 | 0.86 | SMN1; SMN2 (0.60) | KMT2AKDM4EMAPTLMNATSHR | |
| SCHEMBL24328893 | 0.86 | MTNR1A (0.57) | KMT2AKDM4EMAPTLMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117529489-A | Bicyclic peptide ligands specific for NK cells | 拜斯科技术开发有限公司 | 2024-02-06 | — | — | CN | claimed |
| US-20160331725-A1 | USE OF COMPOUNDS THAT ARE ABLE TO INCREASE THE SERUM IGF-1 LEVEL FOR THE PREPARATION OF A THERAPEUTICAL COMPOSITION FOR TREATMENT OF VARIOUS DISEASE STATES ASSOCIATED WITH A REDUCED IGF-1 SERUM LEVEL IN HUMANS AND ANIMALS | VEIJLEN N.V. | 2016-11-17 | — | — | US | claimed |
| EP-2513016-B1 | IMPROVED METHOD FOR PRODUCING INTERMEDIATES FOR THE PRODUCTION OF MACROCYCLES THAT ARE INHIBITORS OF THE PROTEASOMIC DEGRADATION OF P27, SUCH AS ARGYRIN AND DERIVATIVES THEREOF | Helmholtz Zentrum für Infektionsforschung GmbH (DE) | 2016-02-17 | — | — | EP | claimed |
| US-8853249-B2 | Method for producing intermediates for the production of macrocycles that are inhibitors of the proteasomic degradation of p27, such as argyrin and derivatives thereof | Helmholtz-Zentrum für Infektionsforschungs GmbH (DE) | 2014-10-07 | — | — | US | claimed |
| US-20120295941-A1 | Method For Producing Intermediates For The Production Of Macrocycles That Are Inhibitors Of The Proteasomic Degradation of P27, Such As Argyrin And Derivatives Thereof | GOTTFRIED WILHELM LEIBNIZ UNIVERSITAT (DE) | 2012-11-22 | — | — | US | claimed |
| EP-2513016-A1 | IMPROVED METHOD FOR PRODUCING INTERMEDIATES FOR THE PRODUCTION OF MACROCYCLES THAT ARE INHIBITORS OF THE PROTEASOMIC DEGRADATION OF P27, SUCH AS ARGYRIN AND DERIVATIVES THEREOF | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2012-10-24 | — | — | EP | claimed |
| EP-2303916-B1 | METHOD FOR PRODUCING INTERMEDIATES FOR THE PRODUCTION OF NOVEL MACROCYCLES THAT ARE INHIBITORS OF THE PROTEASOMIC DEGRADATION OF P27, SUCH AS ARGYRIN AND DERIVATIVES THEREOF, AND USES OF SAID MACROCYCLES | HELMHOLTZ INFEKTIONSFORSCHUNG (DE) | 2012-05-09 | — | — | EP | claimed |
| US-20110311564-A1 | Method for Producing Intermediates for the Production of Novel Macrocycles that are Inhibitors of the Proteasomic Degradation of p27, such as Argyrin and Derivatives Thereof, and Uses of Said Macrocycles | GOTTFRIED WILHELM LEIBNIZ UNIVERSITAT HANNOVER (DE) | 2011-12-22 | — | — | US | claimed |
| WO-2011073173-A1 | IMPROVED METHOD FOR PRODUCING INTERMEDIATES FOR THE PRODUCTION OF MACROCYCLES THAT ARE INHIBITORS OF THE PROTEASOMIC DEGRADATION OF P27, SUCH AS ARGYRIN AND DERIVATIVES THEREOF | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2011-06-23 | — | — | WO | claimed |
| EP-2303916-A1 | METHOD FOR PRODUCING INTERMEDIATES FOR THE PRODUCTION OF NOVEL MACROCYCLES THAT ARE INHIBITORS OF THE PROTEASOMIC DEGRADATION OF P27, SUCH AS ARGYRIN AND DERIVATIVES THEREOF, AND USES OF SAID MACROCYCLES | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2011-04-06 | — | — | EP | claimed |
| JP-4641942-B2 | — | — | 2011-03-02 | — | — | JP | claimed |
| WO-2010006682-A1 | METHOD FOR PRODUCING INTERMEDIATES FOR THE PRODUCTION OF NOVEL MACROCYCLES THAT ARE INHIBITORS OF THE PROTEASOMIC DEGRADATION OF P27, SUCH AS ARGYRIN AND DERIVATIVES THEREOF, AND USES OF SAID MACROCYCLES | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2010-01-21 | — | — | WO | claimed |
| EP-2138507-A1 | Method for producing intermediates for the production of novel macrocycles that are inhibitors of the proteasomic degradation of p27, such as argyrin and derivatives thereof, and uses of said macrocycles | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2009-12-30 | — | — | EP | claimed |
| US-20080194553-A1 | compounds that are capable of increasing the serum level of insulin-like growth factor 1 (IGF-1) for the preparation of a therapeutical composition,in the form of a food supplement, for the treatment of subjects suffering from serious fatigue and exhausting symptoms, burn-out and chronic fatigue syndrome | VEIJLEN N.V. (NL) | 2008-08-14 | — | — | US | claimed |
| EP-1670444-A2 | USE OF INDOLEACETIC ACID DERIVATIVES WHICH INCREASE THE SERUM IGF-1 LEVEL FOR THE PREPARATION OF A THERAPEUTICAL COMPOSITION FOR TREATMENT OF VARIOUS DISEASES | Veijlen N.V. (AN) | 2006-06-21 | — | — | EP | claimed |
| WO-2005039546-A2 | USE OF INDOLEACETIC ACID DERIVATIVES WHICH INCREASE THE SERUM IGF-1 LEVEL FOR THE PREPARATION OF A THERAPEUTICAL COMPOSITION FOR TREATMENT OF VARIOUS DISEASES | VEIJLEN N.V. (AN) | 2005-05-06 | — | — | WO | claimed |
| CN-122094701-A | TLR3 binding bicyclic peptide ligands | — | 2026-05-26 | — | — | CN | disclosed |
| EP-3894390-B1 | SYNTHESIS OF (S)-6-HYDROXYTRYPTOPHAN AND DERIVATIVES THEREOF | HEIDELBERG PHARMA RES GMBH (DE) | 2026-05-20 | — | — | EP | disclosed |
| WO-2005039546-A2 | USE OF INDOLEACETIC ACID DERIVATIVES WHICH INCREASE THE SERUM IGF-1 LEVEL FOR THE PREPARATION OF A THERAPEUTICAL COMPOSITION FOR TREATMENT OF VARIOUS DISEASES | VEIJLEN N.V. (AN) | 2005-05-06 | — | — | WO | disclosed |
| WO-2005034942-A1 | ANIMAL FEED COMPOSITION | VEIJLEN N.V. (AN) | 2005-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295941-A1 | Method For Producing Intermediates For The Production Of Macrocycles That Are Inhibitors Of The Proteasomic Degradation of P27, Such As Argyrin And Derivatives Thereof | SKP2, CDKN1A, MDM2 | KMT2A 1847/4885KDM4E 1914/4885MAPT 3445/4885 |
| US-20110311564-A1 | Method for Producing Intermediates for the Production of Novel Macrocycles that are Inhibitors of the Proteasomic Degradation of p27, such as Argyrin and Derivatives Thereof, and Uses of Said Macrocycles | SKP2, CDKN1A, PSMC1 | KMT2A 1824/4885KDM4E 1695/4885MAPT 4040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.